GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Sai Life Sciences Ltd

Sai Life Sciences: Q2 FY27 Revenue up 23% YoY to ₹659 crore, PAT up 17%

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 06 Nov 2026, 12:13 AM IST  ·  BSE ID: 4fe1a9b6-d7e5-4325-bec1-863aa75e2636
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's revenue and profit grew significantly in the second quarter and first half of the financial year.
🤖 AI Summary
  • Sai Life Sciences reported Q2 FY27 revenue from operations of ₹659 crore, a 23% increase year-on-year.
  • Net Profit (PAT) for Q2 FY27 stood at ₹98 crore, reflecting a 17% year-on-year growth.
  • For the half year ended 30 September 2026 (H1 FY27), revenue from operations was ₹1,213 crore, up 17% YoY.
  • H1 FY27 PAT increased 19% year-on-year to ₹172 crore.
  • The company incurred Capex of ₹621 crore in H1 FY27 for capacity and capability expansion.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
₹ 659 crores
23%
EBITDA (Q2 FY27)
₹ 187 crores
20%
PAT (Q2 FY27)
₹ 98 crores
17%
Revenue from Operations (H1 FY27)
₹ 1,213 crores
17%
EBITDA (H1 FY27)
₹ 335 crores
19%
PAT (H1 FY27)
₹ 172 crores
19%
Capex (H1 FY27)
₹ 621 crores
🏢 How This Affects the Company
📈
Business Impact
The company reported broad-based growth in both CRO and CDMO segments, indicating sustained business momentum and increasing traction with global pharmaceutical companies for integrated outsourcing.
💰
Financial Impact
Revenue from operations increased by 23% year-on-year in Q2 FY27 and 17% for H1 FY27. EBITDA margins stood at 28% for both Q2 FY27 and H1 FY27, while PAT margins were 15% and 14% respectively.
⚙️
Operational Impact
The company's capacity and capability expansion program remains on track, with ₹621 crore invested in Capex during H1 FY27, supporting long-term customer requirements.
👥 What This Means For Shareholders
✅
Action Required
No specific action required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, which showed year-on-year increases in revenue and net profit.
🔍
Management Signal
Management indicates a focus on continued business momentum, integrated outsourcing, and strategic investments in capacity and capabilities to support future growth.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — assess continued revenue and profit growth trends.
Updates on capacity and capability expansion projects — verify capital expenditure effectiveness.
Earnings call on November 06, 2026 at 11:00 AM (IST) for management insights.
LOW RISK The filing reports consistent growth in revenue and profit with stable margins.
💡 Investor Takeaway
Sai Life Sciences' Q2 FY27 revenue from operations grew 23% year-on-year to ₹659 crore, with PAT rising 17% to ₹98 crore. Half-year revenue increased 17% to ₹1,213 crore and PAT grew 19% to ₹172 crore. The company invested ₹621 crore in Capex during H1 FY27, maintaining a 28% EBITDA margin.
⚖️ Strengths & Concerns

✅ Positives

  • Revenue from operations for Q2 FY27 increased by 23% year-on-year to ₹659 crore, demonstrating strong top-line growth.
  • EBITDA margin was sustained at 28% in Q2 FY27, indicating healthy operating performance despite growth initiatives.

⚠️ Concerns

  • EBITDA Margin percentage for Q2 FY27 decreased slightly to 28% from 29% in Q2 FY26.
  • PAT Margin percentage for Q2 FY27 decreased to 15% from 16% in Q2 FY26.
📅 Company Track Record
Sai Life Sciences previously reported Q1 FY27 net profit rose 22% to ₹73 crore, with revenue up 12%. For the full FY26, Net Profit (PAT) increased 109% to ₹355 crore, and Revenue was up 29% to ₹2,192 crore, indicating a trend of strong financial performance.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Sai Life Sciences' revenue from operations in Q2 FY27?
Sai Life Sciences reported revenue from operations of ₹659 crore for Q2 FY27, an increase of 23% compared to Q2 FY26.
What was the Net Profit (PAT) for Sai Life Sciences in Q2 FY27?
Net Profit (PAT) for Sai Life Sciences in Q2 FY27 was ₹98 crore, marking a 17% year-on-year increase.
What was the EBITDA margin for Sai Life Sciences in Q2 FY27?
The EBITDA margin for Sai Life Sciences in Q2 FY27 was 28%, compared to 29% in Q2 FY26.
How much Capex did Sai Life Sciences incur in H1 FY27?
Sai Life Sciences incurred Capex of ₹621 crore in H1 FY27 as part of its capacity and capability expansion programme.
What was the half-year revenue for Sai Life Sciences for H1 FY27?
For the half year ended 30 September 2026 (H1 FY27), Sai Life Sciences reported revenue from operations of ₹1,213 crore, a 17% increase from H1 FY26.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.